Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force.
De Marinis F, Rinaldi M, Ardizzoni A, Bruzzi P, Pennucci MC, Portalone L, D'Aprile M, Ripanti P, Romano F, Belli M, Altavilla G, Migliorino MR, Rosso R, Salvati F. De Marinis F, et al. Among authors: portalone l. Tumori. 1999 May-Jun;85(3):177-82. doi: 10.1177/030089169908500306. Tumori. 1999. PMID: 10426128 Clinical Trial.
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.
Ardizzoni A, Addamo GF, Baldini E, Borghini U, Portalone L, De Marinis F, Lionetto R, Conte PF, Bruzzi P, Pennucci MC, et al. Ardizzoni A, et al. Among authors: portalone l. Br J Cancer. 1995 Jan;71(1):115-9. doi: 10.1038/bjc.1995.23. Br J Cancer. 1995. PMID: 7529522 Free PMC article. Clinical Trial.
Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Migliorino MR, Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bandera M, Pennucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M, Rosso R, et al. Baldini E, et al. Among authors: portalone l. Br J Cancer. 1998 Jun;77(12):2367-70. doi: 10.1038/bjc.1998.393. Br J Cancer. 1998. PMID: 9649160 Free PMC article. Clinical Trial.
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
Portalone L, Antilli A, Nunziati F, Crispino C, de Marinis F, Friggeri L, Lombardi A, Lorusso V, Pronzato P, Sambiasi D, Signora M; Associazione Italiana Pneumologi Ospedalieri Thoracic Oncology Study Group. Portalone L, et al. Tumori. 2005 Jan-Feb;91(1):15-8. doi: 10.1177/030089160509100104. Tumori. 2005. PMID: 15849999 Clinical Trial.
31 results